| Statement of Dr. Paul A. Sieving on the Passing
of Dr. Muriel Isolde Kaiser-Kupfer
As director of the National Eye Institute (NEI), one of the National
Institutes of Health, I am sad to report that Muriel Isolde Kaiser-Kupfer,
M.D., researcher in genetic eye diseases and chief of NEI's Ophthalmic
Genetics and Visual Function Branch until her retirement in 2004,
passed away January 9, 2008 after a lengthy illness.
Kim, as she was known to many of her friends and colleagues, was
an accomplished scientist. She had remarkable success in reducing
visual loss associated with the metabolic disorders gyrate atrophy
and nephropathic cystinosis. Her stellar career emphasized her
devotion to the care of patients with these rare diseases. She
will be remembered for her focus on patients and her commitment
to linking laboratory findings to clinical treatments that improved
people's eyesight.
Originally from New York, Dr. Kaiser-Kupfer spent part of her
childhood in Florida, where at the age of 14 she was a champion
diver. She graduated from Wellesley College in 1957 and earned
her M.D. from Johns Hopkins University School of Medicine in 1961.
She was one of only four women in the class. She then completed
a pediatric internship, residency, and fellowship, and served as
assistant director and instructor at the Johns Hopkins University
Hospital until 1968. From 1968 to 1970, she completed a residency
in ophthalmology and served as a consultant in the congenital defects
clinic at the University of Washington School of Medicine in Seattle.
She was one of the few women physicians of her era who were board
certified in both pediatrics and ophthalmology.
Dr. Kaiser-Kupfer joined NEI in 1972 and from 1974 through 2004
served in a number of leadership roles: founding member of the
NIH Medical Genetics Training Program, medical officer in NEI's
Ophthalmology and Pediatrics Clinical Branch, section chief and
branch chief of Ophthalmic Genetics and Visual Function, NEI representative
to the NIH Inter-Institute Genetics Group, and deputy clinical
director.
In addition to researching gyrate atrophy and cystinosis, Dr.
Kaiser-Kupfer pioneered new ways to diagnose and treat other hereditary
diseases such as neurofibromatosis II, congenital cataracts, and
anomalies of the anterior segment. She was the author or co-author
of more than 100 scientific papers, and she mentored and inspired
many medical students, residents, and fellows. In addition, she
volunteered with the Maryland School for the Blind and gave hope
to many young people there who were then seen and treated at NEI.
Because she spoke Spanish, she saw many Hispanic patients with
congenital and hereditary diseases.
For much of her 30-year career, Dr. Kaiser-Kupfer focused on gyrate
atrophy, which causes retinal degeneration and resulting visual
disability by the age of 50 or 60. She and her colleague, Dr. David
Valle of Johns Hopkins University School of Medicine, conducted
an 18-year study of the disease in patients from many parts of
the world, and discovered that it was caused by an enzyme deficiency.
They then proved that a diet restricted in arginine, an amino acid,
slows the progression of the disease.
Another disease to which Dr. Kaiser-Kupfer devoted much of her
research and clinical work was nephropathic cystinosis, a rare
disease that eventually causes kidney failure at about ten years
of age. In this disorder crystals of cystine begin to build up
in the cornea by one year of age. Cystine is a component of protein
found in hair, skin, and other tissues of the body. As the number
of crystals increases in the cornea, patients experience severe
pain and have difficulty keeping their eyes open. Occasionally
the crystals break through the corneal surface, causing the cornea
to become hazy and resulting in vision loss.
Seeking treatment for the children with this devastating disorder,
Dr. Kaiser-Kupfer worked with long-term collaborator and cystinosis
expert William A. Gahl, M.D., Ph.D., clinical director in the National
Human Genome Research Institute. The two tested the use of topical
cysteamine, a byproduct of the amino acid cysteine, on animal corneas.
They then conducted a human clinical trial that demonstrated the
disappearance of the crystals and the resulting relief of pain
and improvement of vision. In 1987, Kaiser-Kupfer published a study
in the New England Journal of Medicine that described
the successful removal of crystals from the cornea by use of cysteamine.
Dr. Gahl, in his recollections at Kaiser-Kupfer's memorial service,
described what it was like to know and work with her. "Kim
developed eye drops to deliver cysteamine directly to the cornea," he
explained. "After a few months of treatment, the crystals
actually dissolved and for hundreds of patients the pain was gone.
It was a miracle. Kim herself was a miracle. In her professional
interactions, she displayed the grace and form of the competitive
diver that she was. She provided care at every visit, but discoveries
for all time. She was an excellent pediatrician, a great ophthalmologist,
a fine person, and a wonderful friend."
In 1990, Dr. Kaiser-Kupfer received the Lifetime Achievement Award
from the Cystinosis Foundation for her role in developing the cystinosis
treatment. After her retirement from NEI, she was honored by the
National Library of Medicine in its ongoing series called "Local
Legends: Celebrating America's Local Women Physicians."
Dr. Kaiser-Kupfer is survived by her husband, Dr. Carl Kupfer,
founding NEI director, their children Charles and Sarah, and four
grandchildren.
The National Eye Institute (NEI) is part of the National Institutes
of Health (NIH) and is the federal government's lead agency for
vision research that leads to sight-saving treatments and plays
a key role in reducing visual impairment and blindness. For more
information, visit the NEI Website at http://www.nei.nih.gov.
The National Institutes of Health (NIH) — The Nation's
Medical Research Agency — includes 27 Institutes and
Centers and is a component of the U.S. Department of Health and
Human Services. It is the primary federal agency for conducting
and supporting basic, clinical and translational medical research,
and it investigates the causes, treatments, and cures for both
common and rare diseases. For more information about NIH and
its programs, visit www.nih.gov.
|